Group 1 - The core viewpoint of the news is the strategic partnership between Huajian Medical and Renhe Pharmaceutical's subsidiary to establish the world's first OTC-focused RWA exchange in the U.S. [1] - This collaboration is a key step in Huajian Medical's "ETHK blockchain financial ecosystem strategy" and aims to create a replicable model to validate the feasibility and potential of this innovative approach [1][2] - Huajian Medical will provide compliance operational support through ETHK Inc, while Huajian Digital Industry Development (Shenzhen) Co., Ltd. will handle technology development [1] Group 2 - Renhe Pharmaceutical, a leading player in China's OTC market, aims to revitalize its brand and intangible assets through this partnership, especially after facing revenue declines of 16.46% and net profit drops of 13.87% in the first half of the year [1] - The collaboration is expected to generate significant technical service revenue for Huajian Medical and validate its light-asset, replicable empowerment model [2] - The "ETHK global RWA exchange" model is designed to connect the industry and financial sectors, providing asset selection, structural design, compliance issuance, and liquidity management services [2]

Group 1 - The core viewpoint of the news is that Huajian Medical and Renhe Pharmaceutical have established a strategic partnership to create the world's first specialized trading platform for Real World Assets (RWA) in the over-the-counter (OTC) drug sector [1][2] - The platform will adhere to securities-level standards and aims to provide an efficient, transparent, and compliant digital trading venue for intangible assets such as intellectual property, future revenue rights, and brand value in the OTC industry [1][2] - Renhe Pharmaceutical, as the president unit of the China OTC Association, plays a significant role in industry policy discussions and standard-setting, leveraging its competitive position in the Chinese OTC market to lead industry development [1][2] Group 2 - This strategic cooperation marks a new phase for the "ETHK" blockchain financial ecosystem strategy, showcasing the innovative "ETHK Global RWA Trading Exchange" business model on a global stage [2] - The collaboration reflects the company's commitment to creating a truly open and empowering digital financial ecosystem through cutting-edge technology and rigorous compliance practices [2] - The ultimate mission of financial technology is to serve the real economy and create inclusive value, with the partnership exemplifying this belief [2] Group 3 - The board believes that this strong alliance will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [3] - The collaboration aims to ensure the successful launch and stable operation of the world's first OTC RWA exchange by pooling the strengths and resources of both parties [3] - The partnership is expected to inject strong momentum into the sustainable business growth and financial performance of the group [3]

Core Viewpoint - Huajian Medical (01931) has announced a strategic partnership with Renhe Pharmaceutical (000650.SZ) to establish the world's first vertical RWA exchange focused on the OTC sector in the United States, marking a significant step in the implementation of its "ETHK blockchain financial ecosystem strategy" [1][2] Group 1: Strategic Collaboration - The collaboration with Renhe Pharmaceutical signifies a new phase in the large-scale implementation and value realization of the "ETHK" blockchain financial ecosystem strategy [1] - This partnership serves as a benchmark case for the innovative "ETHK global RWA exchange" business model, aiming to create a replicable model that validates the feasibility and potential of this innovation [1] Group 2: Vision and Mission - The company believes that the ultimate mission of financial technology is to serve the real economy and create inclusive value, which this collaboration exemplifies [2] - The goal is to empower classic national brands like Renhe Pharmaceutical to achieve digital transformation and promote successful ecological models across various industries, contributing to national industrial upgrades and the development of the digital economy [2] Group 3: Future Outlook - The board is confident that this strong alliance will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [2] - The company aims to ensure the successful launch and stable operation of the world's first OTC RWA exchange through close collaboration with Renhe Pharmaceutical, leveraging both parties' resources [2]

Core Viewpoint - The strategic partnership between Huajian Medical and Renhe Pharmaceutical aims to establish the world's first vertical RWA exchange focused on the OTC sector in the United States, marking a significant step in Huajian's ETHK blockchain financial ecosystem strategy [1][2] Group 1: Strategic Collaboration - The collaboration with Renhe Pharmaceutical represents a key milestone in the implementation of Huajian's ETHK blockchain financial ecosystem strategy and the innovative "ETHK global RWA exchange" business model [1] - This partnership is intended to create a replicable model that validates the feasibility and potential of the innovative approach [1] Group 2: Commitment to Economic Development - Huajian Medical emphasizes that the ultimate mission of financial technology is to serve the real economy and create inclusive value, which this collaboration exemplifies [2] - The company aims to leverage technology to assist classic national brands like Renhe Pharmaceutical in their digital transformation, promoting successful ecological models across various industries [2] Group 3: Future Growth and Synergy - The board believes that this collaboration will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [2] - Huajian Medical plans to work closely with Renhe Pharmaceutical to ensure the successful launch and stable operation of the world's first OTC RWA exchange, aiming for high standards and quality [2]

Group 1 - The core viewpoint of the news is that Huajian Medical and Renhe Pharmaceutical have established a strategic partnership to create the world's first specialized trading platform for over-the-counter (OTC) real-world assets (RWA) [1][2] - The platform will adhere to securities-level standards and aims to provide an efficient, transparent, and compliant digital trading venue for intangible assets and product rights in the OTC industry, addressing a critical gap in the global market [1][2] - Renhe Pharmaceutical, as the president unit of the China OTC Association, plays a significant role in industry policy discussions and standard-setting, leveraging its competitive position in the Chinese OTC market to lead industry development [1] Group 2 - This strategic cooperation marks a new phase for the "ETHK" blockchain financial ecosystem strategy, showcasing the innovative "ETHK global RWA trading platform" model on a global stage [2] - The collaboration reflects the company's commitment to using cutting-edge technology and rigorous compliance practices to build an open and empowering digital financial ecosystem [2] - The partnership aims to facilitate the digital transformation of classic national brands like Renhe Pharmaceutical, contributing to national industrial upgrades and the development of the digital economy [2] Group 3 - The board believes that this collaboration will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [3] - The companies will work closely to ensure the successful launch and stable operation of the world's first OTC RWA trading platform, leveraging their combined resources [3]

Core Viewpoint - The strategic partnership between Huajian Medical and Renhe Pharmaceutical aims to establish the world's first specialized trading platform for over-the-counter (OTC) real-world assets (RWA), addressing a significant gap in the global market [1][2]. Group 1: Strategic Collaboration - The collaboration signifies a new phase in Huajian Medical's "ETHK" blockchain financial ecosystem strategy, marking the global debut of its innovative "ETHK Global RWA Exchange" business model [2]. - Renhe Pharmaceutical, as the president unit of the China OTC Association, plays a crucial role in industry policy discussions and standard-setting, leveraging its strong market position to lead the development of the OTC sector [1][2]. Group 2: Goals and Vision - The partnership reflects the commitment to create a transparent, efficient, and compliant digital trading platform for intangible assets and product rights in the OTC industry, ultimately serving the broader goal of enhancing the digital economy and national industrial upgrades [2]. - The collaboration is expected to generate significant synergies, driving strategic transformation and value reassessment for both companies, while ensuring the successful launch and operation of the OTC RWA exchange [3].

Group 1 - The company has announced a strategic partnership with Renhe Pharmaceutical's wholly-owned subsidiary, Renhe International, to establish the world's first vertical RWA exchange focused on the OTC (over-the-counter) drug sector in the United States [1]

與 仁 和 藥 業（000650.SZ） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 全資附屬公司仁和國際達成重大戰略合作 與 仁 和 藥 業（000650.SZ）間 接 全 資 附 屬 公 司 仁 和 國 際 達 成 重 大 戰 略 合 作，於 美 國 共 同 籌 建 全 球 首 家 非 處 方 藥（OTC）垂 直 領 域RWA交 易 所。 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 的 最 新 資 料。 一、前 言：ETHK生態戰略的系統性深化 茲提述本公司日期為2025年 ...

资料显示，仁和药业股份有限公司位于江西省南昌市红谷滩新区红谷中大道998号绿地中央广场B区元 创国际18层，成立日期1996年12月4日，上市日期1996年12月10日，公司主营业务涉及生产、销售中西 药、原料药及健康相关产品,包括口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用 洗剂、搽剂、栓剂、软膏剂等剂型药品以及健康相关产品。主营业务收入构成为：药品70.25%，健康 相关产品27.79%，其他业务产品1.95%。 从仁和药业十大流通股东角度 数据显示，南方基金旗下1只基金位居仁和药业十大流通股东。南方中证1000ETF（512100）二季度增 持193.77万股，持有股数1033.67万股，占流通股的比例为0.78%。根据测算，今日浮盈赚取约351.45万 元。 9月16日，仁和药业涨5.33%，截至发稿，报6.72元/股，成交2.65亿元，换手率3.01%，总市值94.08亿 元。 南方中证1000ETF（512100）基金经理为崔蕾。 截至发稿，崔蕾累计任职时间6年315天，现任基金资产总规模949.76亿元，任职期间最佳基金回报 147.61%， 任职期间最差基金回报-15.93%。 ...

Group 1 - The company has announced the launch of the world's first Ulook AI glasses, which are currently in trial sales [2] - The official WeChat account of the subsidiary, Shining Brand, has published information regarding the Ulook AI glasses [2] - The company clarified that commercial sales of the Ulook glasses have not yet commenced [2]